Literature DB >> 34324103

Clinical outcome and endothelial loss following prepupillary and retropupillary implantation of iris claw intraocular lenses.

Ebubekir Durmus1, Fehim Esen2, Melda Yenerel3, Huseyin Sanisoglu4, Halit Oguz2.   

Abstract

PURPOSE: Iris claw intraocular lenses (IOLs) were successfully used for the management of aphakia in patients that lack capsular support. The aim of this study was to compare the clinical outcome of prepupillary and retropupillary implantation of these IOLs.
METHODS: The files of the 26 patients that had an iris claw IOL implantation between 2010 and 2020 were retrospectively reviewed. Detailed ophthalmological examination findings including corrected distance visual acuity (CDVA), intraocular pressure, endothelial cell counts, slit lamp and dilated fundus examination findings were specifically tabulated. Intraoperative and postoperative complications were also specifically recorded.
RESULTS: There were 18 patients in the prepupillary implantation group and eight patients in the retropupillary implantation group. Age and gender distribution were similar between the groups. CDVA significantly increased in prepupillary and retropupillary implantation groups (p = 0.001 and p = 0.012, respectively). Median endothelial cell loss was 6.7% in prepupillary group and 7.2% in retropupillary group. The only intraoperative complication was iridodialysis (n = 1). Postoperative complications included retinal detachment (n = 1), cystoid macular edema (n = 2) and IOL tilt (n = 1). All of these complications occurred in the prepupillary implantation group.
CONCLUSION: Prepupillary and retropupillary implantation of iris claw IOLs resulted with similar visual gain and endothelial loss rates in a follow-up time of 6 months. There was an insignificant trend toward a reduced complication rate following retropupillary implantation.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Aphakia; Iris claw intraocular lens; Secondary intraocular lens implantation

Year:  2021        PMID: 34324103     DOI: 10.1007/s10792-021-01965-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  28 in total

1.  [Characteristics and management of Uveitis-Glaucoma-Hyphema syndrome].

Authors:  M Duchêne; C Iscar; M Muraine; J Gueudry
Journal:  J Fr Ophtalmol       Date:  2020-01-22       Impact factor: 0.818

2.  Secondary IOL versus Epi-K.

Authors:  D B Davis
Journal:  Indian J Ophthalmol       Date:  1989 Apr-Jun       Impact factor: 1.848

3.  Long-term Outcomes and Complications of the New Carlevale Sutureless Scleral Fixation Posterior Chamber IOL.

Authors:  Agostino S Vaiano; Kenneth J Hoffer; Antonio Greco; Andrea Greco; Giovanni D'Amico; Valerio Pasqualitto; Carlo Carlevale; Giacomo Savini
Journal:  J Refract Surg       Date:  2021-02-01       Impact factor: 3.573

4.  Keratophakia and keratomileusis--clinical results.

Authors:  C A Swinger; J I Barraquer
Journal:  Ophthalmology       Date:  1981-08       Impact factor: 12.079

5.  Secondary lens implantation in aphakia: visual results and complications.

Authors:  H J Shammas; C F Milkie
Journal:  J Am Intraocul Implant Soc       Date:  1978-10

6.  [Complications of epikeratophakia in correction of aphakia, myopia, hyperopia and keratoconus].

Authors:  G Grabner
Journal:  Fortschr Ophthalmol       Date:  1991

7.  Ex vivo photoactivated chromophore for keratitis-corneal crosslinking on inverted graft: new approach to manage interface infectious keratitis after deep anterior lamellar keratoplasty.

Authors:  Alessandro Mularoni; Laura Rania; Aurelio Imburgia; Vincenzo Scorcia; Giuseppe Giannaccare
Journal:  J Cataract Refract Surg       Date:  2020-12       Impact factor: 3.351

8.  Long-term follow-up of epikeratophakia.

Authors:  Julia Kang; Florence Cabot; Sonia H Yoo
Journal:  J Cataract Refract Surg       Date:  2014-12-20       Impact factor: 3.351

9.  Epikeratophakia: the surgical correction of aphakia. III. Preliminary results of a prospective clinical trial.

Authors:  T P Werblin; H E Kaufman; M H Friedlander; N Granet
Journal:  Arch Ophthalmol       Date:  1981-11

10.  The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.

Authors:  Mehmet Orkun Sevik; Aslan Aykut; Gamze Özkan; Volkan Dericioğlu; Özlem Şahin
Journal:  Int Ophthalmol       Date:  2021-04-17       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.